These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21575475)

  • 1. [Relationship between the Akt-regulated direct p53 mitochondrial translocation and the resistance to cisplatin of ovarian cancer cells].
    Zhou Y; Wang SY; Yang XK; Wang HM
    Zhonghua Zhong Liu Za Zhi; 2011 Feb; 33(2):97-100. PubMed ID: 21575475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Inhibition of mitochondrial Smac release by Akt in chemoresistant ovarian cancer cells].
    Yang XK; Wang JD; Wang SY; Zhang YX
    Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):259-62. PubMed ID: 18788627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway.
    Yang X; Fraser M; Moll UM; Basak A; Tsang BK
    Cancer Res; 2006 Mar; 66(6):3126-36. PubMed ID: 16540663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
    Fraser M; Bai T; Tsang BK
    Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
    Yan X; Fraser M; Qiu Q; Tsang BK
    Gynecol Oncol; 2006 Aug; 102(2):348-55. PubMed ID: 16545436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells.
    Fraser M; Leung BM; Yan X; Dan HC; Cheng JQ; Tsang BK
    Cancer Res; 2003 Nov; 63(21):7081-8. PubMed ID: 14612499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein.
    Abedini MR; Muller EJ; Bergeron R; Gray DA; Tsang BK
    Oncogene; 2010 Jan; 29(1):11-25. PubMed ID: 19802016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms.
    Wu H; Cao Y; Weng D; Xing H; Song X; Zhou J; Xu G; Lu Y; Wang S; Ma D
    Cancer Lett; 2008 Nov; 271(2):260-71. PubMed ID: 18657898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mTORC2 component rictor contributes to cisplatin resistance in human ovarian cancer cells.
    Im-aram A; Farrand L; Bae SM; Song G; Song YS; Han JY; Tsang BK
    PLoS One; 2013; 8(9):e75455. PubMed ID: 24086535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
    Puca R; Nardinocchi L; Pistritto G; D'Orazi G
    Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
    Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
    Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 is required for cisplatin-induced processing of the mitochondrial fusion protein L-Opa1 that is mediated by the mitochondrial metallopeptidase Oma1 in gynecologic cancers.
    Kong B; Wang Q; Fung E; Xue K; Tsang BK
    J Biol Chem; 2014 Sep; 289(39):27134-27145. PubMed ID: 25112877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hsp70 promotes chemoresistance by blocking Bax mitochondrial translocation in ovarian cancer cells.
    Yang X; Wang J; Zhou Y; Wang Y; Wang S; Zhang W
    Cancer Lett; 2012 Aug; 321(2):137-43. PubMed ID: 22281241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of AKT sensitizes chemoresistant ovarian cancer cells to cisplatin by abrogating S and G2/M arrest.
    Zhang D; Piao HL; Li YH; Qiu Q; Li DJ; Du MR; Tsang BK
    Exp Mol Pathol; 2016 Jun; 100(3):506-13. PubMed ID: 27163202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.
    Asselin E; Mills GB; Tsang BK
    Cancer Res; 2001 Mar; 61(5):1862-8. PubMed ID: 11280739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells.
    Yang H; He L; Kruk P; Nicosia SV; Cheng JQ
    Int J Cancer; 2006 Nov; 119(10):2304-12. PubMed ID: 16894566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells.
    Sasaki H; Sheng Y; Kotsuji F; Tsang BK
    Cancer Res; 2000 Oct; 60(20):5659-66. PubMed ID: 11059757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of mitochondria in cisplatin-resistant human ovarian carcinoma cells.
    Hirama M; Isonishi S; Yasuda M; Ishikawa H
    Oncol Rep; 2006 Nov; 16(5):997-1002. PubMed ID: 17016583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.